China · Delayed Price · Currency is CNY Bide Pharmatech Statistics
Total Valuation
Bide Pharmatech has a market cap or net worth of CNY 4.70 billion. The enterprise value is 3.75 billion.
| Market Cap | 4.70B |
| Enterprise Value | 3.75B |
Important Dates
The next confirmed earnings date is Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | Jun 10, 2026 |
Share Statistics
Bide Pharmatech has 86.15 million shares outstanding. The number of shares has decreased by -2.50% in one year.
| Current Share Class | 86.15M |
| Shares Outstanding | 86.15M |
| Shares Change (YoY) | -2.50% |
| Shares Change (QoQ) | -2.18% |
| Owned by Insiders (%) | 51.45% |
| Owned by Institutions (%) | 19.36% |
| Float | 31.31M |
Valuation Ratios
The trailing PE ratio is 28.19.
| PE Ratio | 28.19 |
| Forward PE | n/a |
| PS Ratio | 3.48 |
| PB Ratio | 2.24 |
| P/TBV Ratio | 2.25 |
| P/FCF Ratio | 132.20 |
| P/OCF Ratio | 77.42 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.19, with an EV/FCF ratio of 105.65.
| EV / Earnings | 22.36 |
| EV / Sales | 2.78 |
| EV / EBITDA | 15.19 |
| EV / EBIT | 17.36 |
| EV / FCF | 105.65 |
Financial Position
The company has a current ratio of 7.43, with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.43 |
| Quick Ratio | 4.28 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.55 |
| Debt / FCF | 3.81 |
| Interest Coverage | 46.47 |
Financial Efficiency
Return on equity (ROE) is 8.12% and return on invested capital (ROIC) is 14.78%.
| Return on Equity (ROE) | 8.12% |
| Return on Assets (ROA) | 5.19% |
| Return on Invested Capital (ROIC) | 14.78% |
| Return on Capital Employed (ROCE) | 9.71% |
| Weighted Average Cost of Capital (WACC) | 7.01% |
| Revenue Per Employee | 1.84M |
| Profits Per Employee | 228,713 |
| Employee Count | 734 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 0.87 |
Taxes
In the past 12 months, Bide Pharmatech has paid 45.58 million in taxes.
| Income Tax | 45.58M |
| Effective Tax Rate | 21.35% |
Stock Price Statistics
The stock price has decreased by -6.39% in the last 52 weeks. The beta is 0.52, so Bide Pharmatech's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | -6.39% |
| 50-Day Moving Average | 52.95 |
| 200-Day Moving Average | 62.81 |
| Relative Strength Index (RSI) | 59.45 |
| Average Volume (20 Days) | 1,954,888 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bide Pharmatech had revenue of CNY 1.35 billion and earned 167.88 million in profits. Earnings per share was 1.93.
| Revenue | 1.35B |
| Gross Profit | 577.11M |
| Operating Income | 216.24M |
| Pretax Income | 213.46M |
| Net Income | 167.88M |
| EBITDA | 231.22M |
| EBIT | 216.24M |
| Earnings Per Share (EPS) | 1.93 |
Balance Sheet
The company has 1.08 billion in cash and 135.42 million in debt, with a net cash position of 943.08 million or 10.95 per share.
| Cash & Cash Equivalents | 1.08B |
| Total Debt | 135.42M |
| Net Cash | 943.08M |
| Net Cash Per Share | 10.95 |
| Equity (Book Value) | 2.10B |
| Book Value Per Share | 24.37 |
| Working Capital | 2.03B |
Cash Flow
In the last 12 months, operating cash flow was 60.66 million and capital expenditures -25.13 million, giving a free cash flow of 35.52 million.
| Operating Cash Flow | 60.66M |
| Capital Expenditures | -25.13M |
| Depreciation & Amortization | 14.98M |
| Net Borrowing | -183.09M |
| Free Cash Flow | 35.52M |
| FCF Per Share | 0.41 |
Margins
Gross margin is 42.73%, with operating and profit margins of 16.01% and 12.43%.
| Gross Margin | 42.73% |
| Operating Margin | 16.01% |
| Pretax Margin | 15.80% |
| Profit Margin | 12.43% |
| EBITDA Margin | 17.12% |
| EBIT Margin | 16.01% |
| FCF Margin | 2.63% |
Dividends & Yields
This stock pays an annual dividend of 1.16, which amounts to a dividend yield of 2.13%.
| Dividend Per Share | 1.16 |
| Dividend Yield | 2.13% |
| Dividend Growth (YoY) | 28.89% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 46.92% |
| Buyback Yield | 2.50% |
| Shareholder Yield | 4.71% |
| Earnings Yield | 3.57% |
| FCF Yield | 0.76% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 25, 2023. It was a forward split with a ratio of 1.4.
| Last Split Date | May 25, 2023 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Bide Pharmatech has an Altman Z-Score of 9.04 and a Piotroski F-Score of 6.
| Altman Z-Score | 9.04 |
| Piotroski F-Score | 6 |